Keywords: gsk, flu, vacc, protects, trial, subjects, uk

GSK's flu vacc protects 80% of trial subjects

Article | 26 July 2006

Print This

UK drug major GlaxoSmithKline has reported headline data showing that its H5N1 pandemic flu vaccine achieved a high immune ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in